File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/S0264-410X(01)00158-X
- Scopus: eid_2-s2.0-0035919599
- PMID: 11457548
- WOS: WOS:000170090200017
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Therapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic mice
Title | Therapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic mice |
---|---|
Authors | |
Keywords | Hepatitis B virus Immune tolerance Therapeutic vaccine |
Issue Date | 2001 |
Publisher | Elsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine |
Citation | Vaccine, 2001, v. 19 n. 30, p. 4219-4225 How to Cite? |
Abstract | Therapeutic efficacy of HBsAg-anti-HBs-recombinant DNA harboring hepatitis B virus (HBV) S gene complex was compared with three other therapeutic vaccine candidates (recombinant HBsAg, HBsAg complexed to anti-HBs antibodies and naked plasmid DNA encoding the HBV S gene). After four injections at 3-week intervals, the most pronounced decrease of serum HBsAg, the highest titer of anti-HBs response, the highest level of interferon-γ produced by splenocytes and potent cytotoxicity T cell response were observed in the HBsAg-anti HBs-sDNA immunized group. Reduced expression of HBsAg in hepatocytes was also shown. The therapeutic mechanism of HBsAg-anti-HBs-DNA was speculated as modulation of HBsAg presentation via both endogenous and exogenous pathways. © 2001 Elsevier Science Ltd. All rights reserved. |
Persistent Identifier | http://hdl.handle.net/10722/148265 |
ISSN | 2023 Impact Factor: 4.5 2023 SCImago Journal Rankings: 1.342 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Zheng, B | en_HK |
dc.contributor.author | Ng, MH | en_HK |
dc.contributor.author | He, LF | en_HK |
dc.contributor.author | Yao, X | en_HK |
dc.contributor.author | Chan, KW | en_HK |
dc.contributor.author | Yuen, KY | en_HK |
dc.contributor.author | Wen, YM | en_HK |
dc.date.accessioned | 2012-05-29T06:11:53Z | - |
dc.date.available | 2012-05-29T06:11:53Z | - |
dc.date.issued | 2001 | en_HK |
dc.identifier.citation | Vaccine, 2001, v. 19 n. 30, p. 4219-4225 | en_HK |
dc.identifier.issn | 0264-410X | en_HK |
dc.identifier.uri | http://hdl.handle.net/10722/148265 | - |
dc.description.abstract | Therapeutic efficacy of HBsAg-anti-HBs-recombinant DNA harboring hepatitis B virus (HBV) S gene complex was compared with three other therapeutic vaccine candidates (recombinant HBsAg, HBsAg complexed to anti-HBs antibodies and naked plasmid DNA encoding the HBV S gene). After four injections at 3-week intervals, the most pronounced decrease of serum HBsAg, the highest titer of anti-HBs response, the highest level of interferon-γ produced by splenocytes and potent cytotoxicity T cell response were observed in the HBsAg-anti HBs-sDNA immunized group. Reduced expression of HBsAg in hepatocytes was also shown. The therapeutic mechanism of HBsAg-anti-HBs-DNA was speculated as modulation of HBsAg presentation via both endogenous and exogenous pathways. © 2001 Elsevier Science Ltd. All rights reserved. | en_HK |
dc.language | eng | en_US |
dc.publisher | Elsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine | en_HK |
dc.relation.ispartof | Vaccine | en_HK |
dc.rights | Vaccine. Copyright © Elsevier Ltd. | - |
dc.subject | Hepatitis B virus | en_HK |
dc.subject | Immune tolerance | en_HK |
dc.subject | Therapeutic vaccine | en_HK |
dc.subject.mesh | Animals | en_US |
dc.subject.mesh | Antigen-Antibody Complex - Immunology | en_US |
dc.subject.mesh | Cytokines - Biosynthesis | en_US |
dc.subject.mesh | Dna, Recombinant - Immunology | en_US |
dc.subject.mesh | Hepatitis B - Therapy | en_US |
dc.subject.mesh | Hepatitis B Antibodies - Immunology | en_US |
dc.subject.mesh | Hepatitis B Surface Antigens - Blood - Immunology | en_US |
dc.subject.mesh | Hepatitis B Vaccines - Therapeutic Use | en_US |
dc.subject.mesh | Liver - Pathology - Virology | en_US |
dc.subject.mesh | Mice | en_US |
dc.subject.mesh | Mice, Inbred C57bl | en_US |
dc.subject.mesh | Mice, Transgenic | en_US |
dc.subject.mesh | T-Lymphocytes, Cytotoxic - Immunology | en_US |
dc.title | Therapeutic efficacy of hepatitis B surface antigen-antibodies-recombinant DNA composite in HBsAg transgenic mice | en_HK |
dc.type | Article | en_HK |
dc.identifier.email | Zheng, B: bzheng@hkucc.hku.hk | en_HK |
dc.identifier.email | Ng, MH: hrmmnmh@hkucc.hku.hk | en_HK |
dc.identifier.email | Chan, KW: hrmtckw@hku.hk | en_HK |
dc.identifier.email | Yuen, KY: kyyuen@hkucc.hku.hk | - |
dc.identifier.authority | Zheng, BJ=rp00353 | en_HK |
dc.identifier.authority | Chan, KW=rp00330 | en_HK |
dc.identifier.authority | Yuen, KY=rp00366 | en_HK |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1016/S0264-410X(01)00158-X | en_HK |
dc.identifier.pmid | 11457548 | - |
dc.identifier.scopus | eid_2-s2.0-0035919599 | en_HK |
dc.identifier.hkuros | 62046 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-0035919599&selection=ref&src=s&origin=recordpage | en_HK |
dc.identifier.volume | 19 | en_HK |
dc.identifier.issue | 30 | en_HK |
dc.identifier.spage | 4219 | en_HK |
dc.identifier.epage | 4225 | en_HK |
dc.identifier.isi | WOS:000170090200017 | - |
dc.publisher.place | United Kingdom | en_HK |
dc.identifier.scopusauthorid | Zheng, BJ=7201780588 | en_HK |
dc.identifier.scopusauthorid | Ng, MH=7202076421 | en_HK |
dc.identifier.scopusauthorid | He, LF=55074291500 | en_HK |
dc.identifier.scopusauthorid | Yao, X=34973484500 | en_HK |
dc.identifier.scopusauthorid | Chan, KW=16444133100 | en_HK |
dc.identifier.scopusauthorid | Yuen, KY=36078079100 | en_HK |
dc.identifier.scopusauthorid | Wen, YM=7401776949 | en_HK |
dc.identifier.issnl | 0264-410X | - |